It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity drugs. Currently, the global industry is dominated by GLP-1 (glucagon-like ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...